The grant, stated plainly. On January 10, 2023, Juventas Cell Therapy was issued US11547728B2, covering a CD19-targeted CAR and its use. The CPC tags — A61K 35/17 (lymphocyte therapy), A61P 35/02 (leukemia/lymphoma), C07K 14/70578, C12N 5/0636 (T-cell culture) — describe a construct aimed at the canonical B-cell-malignancy antigen.
Why a catalyst desk maps CD19: it is the antigen behind the first approved CAR-T therapies, so the clinical and regulatory pathway is the most validated in the field. New CD19-directed constructs are competing on durability, manufacturing, and access — and their clinical readouts are the binary events a catalyst calendar tracks.
The disciplined read: a CD19-CAR construct grant is an exclusivity claim on a specific receptor design, not a clinical result. The catalyst value rides on what each program's data show against a validated but competitive benchmark.
What the grant does not say: nothing about a specific readout date, efficacy, safety, or freedom to operate against the foundational CAR and CD19-binder estates. Those are separate facts in separate records.
The takeaway: when building a cell-therapy catalyst calendar, use CD19 construct grants to understand the protected space behind each program, then track the readouts separately. Juventas' January 2023 CD19-CAR grant is a dated marker in the field's most validated lane.